In a report released yesterday, Derek Archila from Wells Fargo assigned a Buy rating to Argenx Se (ARGX – Research Report), with a price target of $478.00. The company’s shares closed yesterday at $396.88.
Archila covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Exelixis, and Argenx Se. According to TipRanks, Archila has an average return of 8.4% and a 44.39% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Argenx Se with a $472.86 average price target, a 19.14% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $471.00 price target.
ARGX market cap is currently $21.16B and has a P/E ratio of -69.06.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Argenx Se (ARGX) Company Description:
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
Read More on ARGX:
- Argenx Highlights 2023 Achievements and Outlook
- Argenx price target raised to EUR 477 from EUR 465 at Morgan Stanley
- argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
- Argenx price target lowered to EUR 490 from EUR 510 at JPMorgan
- Argenx price target raised to $440 from $370 at Truist
